Insigneo Advisory Services LLC Raises Stock Position in Gilead Sciences, Inc. $GILD

Insigneo Advisory Services LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 7,305 shares of the biopharmaceutical company’s stock after purchasing an additional 837 shares during the quarter. Insigneo Advisory Services LLC’s holdings in Gilead Sciences were worth $810,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of GILD. Vanguard Group Inc. boosted its stake in shares of Gilead Sciences by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock worth $13,233,912,000 after acquiring an additional 1,893,401 shares in the last quarter. Geode Capital Management LLC boosted its position in Gilead Sciences by 2.6% during the second quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock worth $3,231,548,000 after purchasing an additional 727,515 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Gilead Sciences by 314.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after purchasing an additional 11,156,382 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Gilead Sciences by 12.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock valued at $1,541,302,000 after buying an additional 1,520,809 shares in the last quarter. Finally, Nuveen LLC purchased a new stake in shares of Gilead Sciences in the first quarter valued at approximately $620,415,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other news, EVP Deborah H. Telman sold 53,646 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total value of $6,590,411.10. Following the sale, the executive vice president directly owned 43,676 shares of the company’s stock, valued at approximately $5,365,596.60. The trade was a 55.12% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the completion of the sale, the insider owned 107,193 shares of the company’s stock, valued at $13,491,310.98. This trade represents a 20.71% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 125,146 shares of company stock valued at $15,148,441 in the last quarter. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Price Performance

Shares of GILD stock opened at $125.27 on Tuesday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The company has a market capitalization of $155.42 billion, a PE ratio of 24.95, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32. The firm’s 50-day moving average is $118.73 and its two-hundred day moving average is $113.94. Gilead Sciences, Inc. has a 12 month low of $88.57 and a 12 month high of $128.70.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The business had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business’s revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the firm earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.99%.

Analysts Set New Price Targets

GILD has been the topic of several research analyst reports. Citigroup lifted their target price on shares of Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Wednesday, October 8th. TD Cowen lifted their price objective on Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Wall Street Zen raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 15th. Argus increased their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Finally, Wolfe Research increased their target price on shares of Gilead Sciences from $135.00 to $140.00 and gave the company an “outperform” rating in a research report on Thursday, October 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $130.65.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.